abstract |
IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25+ and/or CCR4+ cutaneous T cell lymphoma, and other human CD25+ or CCR4+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25+ or CCR4+ Tregs. |